Sea You at Fetch Long Beach
News|Articles|November 17, 2026

Q&A: What longer-acting dermatology options mean for dogs, owners, and clinics

Two familiar dermatology products for dogs are getting updates shaped by veterinarian and pet owner feedback. Here’s what changed and why.

In recent weeks, Zoetis reached 2 regulatory milestones in canine dermatology. The USDA licensed Cytopoint Plus, a longer-acting version of the company’s anti-itch monoclonal antibody. In addition, the FDA approved Convenia RTU for Dogs, a more concentrated formulation of the injectable antibiotic cefovecin.

dvm360 spoke with Richard Goldstein, DVM, DACVIM (SAIM), DECVIM-CA, senior vice president, global chief medical officer, and head of medical affairs at Zoetis, to learn more about both products. Goldstein discusses how customer feedback shaped the updates, how Cytopoint Plus was engineered to last longer without changing how it targets itch, and where the company’s pipeline is headed.

Below is a transcript of the conversation, lightly edited for length and clarity.

dvm360:In the last few weeks, there have been some big regulatory milestones for Convenia RTU for Dogs and Cytopoint Plus. Why are those approvals so important?

Richard Goldstein, DVM, DACVIM (SAIM), DECVIM-CA: Those approvals are part of Zoetis’ entire innovation process, in which we’re identifying veterinarian and pet owner pain points. and developing solutions for them, either within therapeutic areas that we’re already in, such as dermatology with those 2, or within new spaces, as we’ll see in the future.

dvm360: Both of these are new versions of products that have been in use for years. What led to updating them, and how are these new versions different?

Goldstein: Convenia RTU for Dogs is an injectable antibiotic that’s used every 14 days. The beauty of using this type of antibiotic is mostly around compliance: not relying on pet owners trying to give a pill—often against the will of their pet—every day, or 2 or 3 times a day. Convenia RTU for Dogs was developed purposefully to make it easier for pet owners and to drive compliance from a medical perspective.

The original Convenia, which is still available, was not always convenient for larger dogs. Vets were needing to administer large volumes, which became less cost-effective, so a need was identified via Zoetis customers. We always start with customers: What could make our products better? [The answer was] a more concentrated version that would supply a better solution for larger dogs, which became Convenia RTU for Dogs. Obviously, it takes years to go from that suggestion to an idea to bringing it to market, but it’s a more concentrated version of Conveniafor dogsbut specifically geared toward larger dogs, to make it easier, with less volume, and more cost-effective.

dvm360: The release notes that Convenia RTU for Dogs can potentially help avoid antibiotic resistance. Can you tell me a little more about that?

Goldstein: Part of the issue with antibiotic resistance is subdosing: giving 4 days instead of 7 days, giving once a day instead of twice a day, just not meeting the actual daily dose that is required. That all goes away with Convenia and Convenia RTU for Dogs because we know exactly what the blood levels are and what the levels in the tissue are for the full 14 days of the administration.

If the world were perfect and we all administered medications to pets exactly as we were asked to, oral medications could be the standard, but it just doesn’t work that way. We all know that compliance levels are very low. We, as pet owners, all forget to give medications. This way, we take it out of the hands of the pet owner and we say it’s on us. We give you an antibiotic that we know will provide the adequate levels for the full 14 days, hence a better solution for antibiotic resistance.

dvm360: Turning to Cytopoint Plus, the dosing time frame went from 4 to 8 weeks to 75 days. How was that longer interval achieved?

Goldstein: That’s part of the innovation. Cytopoint has been around for a long time. It’s loved in the veterinarian profession. It’s used often. It’s a great solution. It does have that 4- to 8-week duration in the US because there’s variability between dogs.

What we didn’t want to do is change anything about the way it works: where it binds to the interleukin-31 (IL-31) molecule and how that works. So, the innovation here is actually changing a different part of the antibody to allow for the longer-acting piece. Instead of changing where it binds to the IL-31 or how it binds, we’ve changed the part of the antibody that is far away from the IL-31, but it affects how it’s metabolized by the body, so it stays around for longer.

The ability to extend the period and say to pet owners, “You don’t have to come in every 4 to 8 weeks. You can now come in every 75 days for your injection and get that same level of anti-itch protection.,” is meeting a need of convenience but will also drive compliance because, unfortunately, people just can’t do it every month sometimes. Pet owners,, I imagine, will be choosing that often because these pets are not sick, right? They don’t necessarily need to be seen. They’re coming in for the injection, so let’s make it better for them. It’s better medicine to have them come in less often.

There are also some issues in terms of the dosing of Cytopoint, where we need 2 vials at some point for a larger dog. This takes that away as well. So Cytopoint Plus will also be more convenient and more cost-effective for larger dogs.

dvm360: What is the breakthrough with next-generation monoclonal antibodies, and what makes it so scientifically important?

Goldstein: I still consider all monoclonal antibodies a breakthrough. Even though we’re 10 years after the launch of Cytopoint, which was the first monoclonal antibody in veterinary medicine, we’re still early in this journey. In people, there are hundreds of monoclonal antibodies that are used and approved. In veterinary medicine, the whole topic of monoclonal antibodies is still new. You can call it first generation, second generation; Zoetis is still bringing a lot of new monoclonal antibodies to the profession.

The innovation here, though, is not just to say, “OK, we can make a monoclonal antibody that will bind interleukin-31 and will eliminate itch.” We can also adjust the time frame or the frequency that that monoclonal antibody would need to be used by making these changes, for instance, in the Fc part, which, not to get too technical, is the part that doesn’t bind the actual protein. That is a tremendous innovation, and that is a second-generation type thing.

I think we’ll see as we move forward in our portfolio, Zoetis will continue to innovate in terms of longer-acting versions of our current monoclonal antibodies, in addition to going into brand new spaces. We’ll be able to see both things coming in the US in the future: longer-acting versions of our current antibodies as well as completely new spaces. So, the innovation is: Yes, we can make an antibody that will bind to a protein, but we can also determine what the optimal dosage regimen is for that antibody—how often do we want those pets to be coming in?—and try to design an antibody to meet those needs.

dvm360: In the development of both of these drugs, was there anything you saw in the research that made you go, “Oh, wow, this is something really different and really important”?

Goldstein: Yeah, just the fact that we can do that, right? It’s like a designer antibody. You can screen not only for the one that binds where you wanted it to bind to the protein, but also for how long that complex of antibody and protein lasts and determine the duration there. What I saw with this one was that it does just that. Instead of having the 4- to 8-week timeframe, now we’re talking about 75 days. There’s variability there too; some dogs could be longer than that.

That is a real innovation, and understanding how that works on the molecular level, on the antibody level, is just fascinating. We basically tell the body, “Don’t worry about this for a while now. You don’t have to metabolize this antibody yet. Let it sit and come back in a few weeks and think about it then.” Just seeing that work and seeing the data come in and the efficacy for that long duration is really, exciting.

dvm360: Can you tell us about what’s in the development pipeline?

Goldstein: We do have other antibodies approved in Europe right now that are longer-acting antibodies for our pain portfolio. We’ve been very open that we’re going into new spaces. We’re talking about chronic kidney disease. We’re talking about cancer and other spaces. It’s on our website that we have assets being developed in those spaces.

We’ve already been doing a lot of work around the world talking about those disease processes, where we might be interested in certain targets in terms of affecting, for instance, the progression of chronic kidney disease.

dvm360: When can clinics expect Convenia RTU for Dogs and Cytopoint Plus to be available?

Goldstein: We expect to be taking orders and having product available early 2027.

dvm360: If you have any other news-breaking announcements, we’d be happy to listen.

Goldstein: I think these two products are news-breaking. It shows that not only can we develop monoclonal antibodies to meet unmet needs, but we can then design them to last longer. That’s just fascinating from a scientific perspective, but also nice from a “why we’re doing this” [perspective]. We’re not just doing this to do the same thing that other people are doing.

We’re doing this so that when we identify needs that pets have, that pet owners have, that veterinarians have, we can figure out a way to meet those needs. This is a really, really good example. Medically, they’re pretty much the same, right? Cytopoint and Cytopoint Plus are doing the same thing, but Cytopoint Plus adds all these advantages, if people are interested, in not having to come back as often to their [veterinarian] and [being] more convenient. It’s not a brand new category, but it’s making what we have today better. That’s true for both of these products.

Putting this in context with the entire [dermatology] portfolio—the category 15 years ago was steroids for these dogs—it’s been a big area of focus for us, and I’m very proud that we continue to innovate and lead in this area.


Related to this article